Aurinia Pharmaceuticals Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · Canada
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-09-26$13.14 RISE2025-09-30$11.05 PEAK2025-11-26$16.37 61d | -15.9% 4d | Missed | Missed | — | — | +48.1% 57d | Missed |
DROP2024-12-10$10.44 RISE2025-04-08$7.20 PEAK2025-06-27$8.64 199d | -31.0% 119d | Missed | Missed | — | — | +20.0% 80d | Missed |
DROP2023-12-19$9.49 RISE2024-04-18$4.81 PEAK2024-07-11$5.86 205d | -49.3% 121d | Missed | Missed | — | — | +21.8% 84d | Missed |
DROP2023-07-28$12.27 RISE2023-11-01$7.13 PEAK2023-12-19$9.49 144d | -41.9% 96d | Missed | Missed | — | — | +33.1% 48d | Missed |
DROP2023-05-03$11.69 RISE2023-05-31$8.96 PEAK2023-07-28$12.27 86d | -23.4% 28d | Missed | Missed | — | — | +36.9% 58d | Missed |
DROP2023-01-27$9.37 RISE2023-02-16$7.61 PEAK2023-05-03$11.69 96d | -18.8% 20d | Missed | Missed | — | — | +53.6% 76d | Missed |
DROP2022-08-18$8.17 RISE2022-12-27$4.11 PEAK2023-03-24$10.31 218d | -49.7% 131d | Missed | Missed | — | — | +150.9% 87d | Missed |
DROP2022-06-08$12.80 RISE2022-09-07$6.66 PEAK2022-10-20$8.14 134d | -48.0% 91d | Missed | Missed | — | — | +22.2% 43d | Missed |
DROP2022-02-16$19.15 RISE2022-06-14$9.45 PEAK2022-07-08$12.39 142d | -50.7% 118d | Missed | Missed | — | — | +31.1% 24d | Missed |
DROP2021-12-31$22.87 RISE2022-05-09$8.95 PEAK2022-06-08$12.80 159d | -60.9% 129d | Missed | Missed | — | — | +43.1% 30d | Missed |
DROP2021-11-02$32.00 RISE2022-03-14$10.05 PEAK2022-03-24$12.80 142d | -68.6% 132d | Missed | Missed | — | — | +27.4% 10d | Missed |
DROP2021-10-29$33.08 RISE2022-01-27$14.65 PEAK2022-02-16$19.15 110d | -55.7% 90d | Missed | Missed | — | — | +30.7% 20d | Missed |
DROP2021-10-29$33.08 RISE2021-12-01$17.78 PEAK2021-12-27$23.91 59d | -46.3% 33d | Missed | Missed | — | — | +34.5% 26d | Missed |
DROP2021-09-27$23.55 RISE2021-10-06$18.85 PEAK2021-10-29$33.08 32d | -20.0% 9d | Missed | Missed | — | — | +75.5% 23d | Missed |
DROP2021-05-28$14.52 RISE2021-07-26$10.93 PEAK2021-09-27$23.55 122d | -24.7% 59d | Missed | Missed | — | — | +115.5% 63d | Missed |
1–15 / 20 1 / 2 | |||||||
Even though Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) posted strong earnings recently, the stock hasn't reacted in a...
FDA drug approvals are reshaping biotech stocksâtrack key decisions, FDA leadership turmoil, and volatility. Click for a look at the issues surrounding the FDA.
Aurinia Pharmaceuticals Inc. ( NASDAQ:AUPH ) last week reported its latest quarterly results, which makes it a good...
Aurinia (AUPH) delivered earnings and revenue surprises of +38.89% and +0.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharmaceuticals Inc. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported revenue was USD 77.71 million compared to USD 62.47...
ROCKVILLE, Maryland & EDMONTON, Alberta, May 07, 2026--Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals (NASDAQ:AUPH) affirms FY2026 sales outlook from $315.000 million-$325.000 million to $315.000 million-$325.000 million vs $326.190 million estimate.
® Corporate Presentation May 2026 Changing the Trajectory of Autoimmune Diseases Continue LUPKYNIS...
Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.19 by 31.58 percent. This is a 56.25 percent increase over earnings of $0.16 per share
EDMONTON, Alberta — EDMONTON, Alberta — Aurinia Pharmaceuticals Inc. on Thursday reported first-quarter earnings of $34.4 million. The Edmonton, Alberta-based company said it had net income...
AURINIA Pharmaceuticals (AUPH) passes Mark Minervini's Trend Template and High Growth Momentum screen, showing strong technical uptrend and accelerating earnings growth. A powerful stock selection candidate.
ARS Pharmaceuticals, Inc. (SPRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
ARS Pharmaceuticals, Inc. (SPRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Tyvaso, a marketed PAH therapy from United Therapeutics, continued to show potential in another lung condition. Elsewhere, Aurinia inked an acquisition and Lilly built its case for Ebglyss.
Tyvaso, a marketed PAH therapy from United Therapeutics, continued to show potential in another lung condition. Elsewhere, Aurinia inked an acquisition and Lilly built its case for Ebglyss.
ROCKVILLE, Maryland & EDMONTON, Alberta & SOUTH SAN FRANCISCO, California, March 30, 2026--Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced today it has entered into a
Aurinia Pharmaceuticals has overhauled its leadership, appointing Kevin Tang as Chief Executive Officer and principal executive officer, Michael Hearne as Chief Financial Officer and principal financial officer, and Ryan Cole as Chief Operating Officer, while several prior executives, including former CEO Peter Greenleaf, have exited and Greenleaf now serves briefly as a consultant to support the transition. This shift places Tang Capital–aligned executives in all top operating and financial...
Aurinia Pharmaceuticals has overhauled its leadership, appointing Kevin Tang as Chief Executive Officer and principal executive officer, Michael Hearne as Chief Financial Officer and principal financial officer, and Ryan Cole as Chief Operating Officer, while several prior executives, including former CEO Peter Greenleaf, have exited and Greenleaf now serves briefly as a consultant to support the transition. This shift places Tang Capital–aligned executives in all top operating and financial...
Aurinia has undergone a major management overhaul, with fund manager and activist investor Kevin Tang appointed as the CEO. Click to read why AUPH is a Buy.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AUPH | -0.13% | +7.88% | -3.89% | +95.54% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -3.10% | +13.60% | -0.44% | +82.85% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| TwoSigma | quant | 3.43M | $50.81M | 0.04% | Added+74.7% | 2026-03-31 |
| StateStreet | passive | 2.53M | $37.45M | 0.00% | Added+1.0% | 2026-03-31 |
| RenTech | quant | 1.66M | $24.66M | 0.04% | Added+4.6% | 2026-03-31 |
| DEShaw | quant | 1.57M | $23.31M | 0.01% | Added+2.7% | 2026-03-31 |
| FidelityFMR | fundamental | 318.8K | $4.72M | 0.00% | Added+18.8% | 2026-03-31 |
| Wellington | fundamental | 46.9K | $695.24K | 0.00% | Trimmed-12.7% | 2026-03-31 |
| TRowePrice | fundamental | 86.2K | $1.28K | 0.00% | Added+27.9% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-30upcoming | 0.25 | — | — |
| 2026-05-07 | 0.20 | 0.25 | +26.58% |
| 2026-02-26 | 0.22 | 1.53 | +606.14% |
| 2025-11-04 | 0.16 | 0.23 | +43.75% |
| 2025-07-31 | 0.15 | 0.16 | +9.09% |
| 2025-05-12 | 0.10 | 0.16 | +60.00% |
| 2025-02-27 | -0.02 | 0.01 | +162.50% |
| 2024-11-07 | 0.02 | 0.10 | +566.67% |
| 2024-08-01 | 0.01 | 0.01 | +20.05% |
| 2024-05-02 | -0.14 | -0.07 | +48.78% |
| 2024-02-15 | -0.16 | -0.19 | -16.33% |
| 2023-11-02 | -0.17 | -0.09 | +46.15% |
| 2023-08-03 | -0.19 | -0.08 | +57.25% |
| 2023-05-04 | -0.22 | -0.18 | +18.71% |
| 2023-02-28 | -0.27 | -0.18 | +34.03% |
| 2022-11-03 | -0.19 | -0.06 | +68.96% |